Trial Profile
A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors PharmAbcine
- 15 Aug 2022 Planned End Date changed from 15 Oct 2022 to 30 Sep 2022.
- 26 Jan 2021 Planned End Date changed from 30 Apr 2020 to 15 Oct 2022.
- 16 Nov 2020 According to Pharm Abcine media release, results from this trial will be presented at SNO (Society of Neuro-Oncology) 2020.